Multivariate prognostic factor analyses for allografted patients (Cox backward; n = 88)
| End point/variable . | Multivariate analysis (Cox backward) . | |||
|---|---|---|---|---|
| P . | HR . | Lower CL . | Upper CL . | |
| Overall survival | ||||
| Refractory at SCT | .023 | 2.31 | 1.13 | 4.73 |
| TCD vs no TCD | .024 | 2.44 | 1.13 | 5.27 |
| Event-free survival | ||||
| Refractory at SCT | < .001 | 2.77 | 1.50 | 5.09 |
| TCD vs no TCD | < .001 | 2.75 | 1.42 | 5.33 |
| Age (per year) | .038 | 0.96 | 0.924 | 0.998 |
| Relapse incidence | ||||
| TCD vs no TCD | .060 | 2.45 | 0.967 | 6.21 |
| Age (per year) | .008 | 0.943 | 0.902 | 0.985 |
| Nonrelapse mortality | ||||
| Refractory at SCT | < .001 | 5.06 | 1.96 | 13.12 |
| TCD vs no TCD | .057 | 2.75 | 0.969 | 7.80 |
| End point/variable . | Multivariate analysis (Cox backward) . | |||
|---|---|---|---|---|
| P . | HR . | Lower CL . | Upper CL . | |
| Overall survival | ||||
| Refractory at SCT | .023 | 2.31 | 1.13 | 4.73 |
| TCD vs no TCD | .024 | 2.44 | 1.13 | 5.27 |
| Event-free survival | ||||
| Refractory at SCT | < .001 | 2.77 | 1.50 | 5.09 |
| TCD vs no TCD | < .001 | 2.75 | 1.42 | 5.33 |
| Age (per year) | .038 | 0.96 | 0.924 | 0.998 |
| Relapse incidence | ||||
| TCD vs no TCD | .060 | 2.45 | 0.967 | 6.21 |
| Age (per year) | .008 | 0.943 | 0.902 | 0.985 |
| Nonrelapse mortality | ||||
| Refractory at SCT | < .001 | 5.06 | 1.96 | 13.12 |
| TCD vs no TCD | .057 | 2.75 | 0.969 | 7.80 |
Covariates considered for all end points were 17p− versus other or unknown karyotype; purine analogue-resistant versus purine analogue-sensitive versus untested; age (per year); alemtuzumab TCD; nonsibling donor versus sibling donor; refractory disease at SCT, ECOG 0 versus 1, and HCT-CI 0 versus > 0. Only covariates remaining in the final models are listed.
CL indicates confidence limit; SCT, stem cell transplantation; TCD, FC + total body irradiation 2Gy + in vivo alemtuzumab; WMUD, well-matched unrelated donor.